Association of anti-β2-glycoprotein I/HLA-DR complex antibody with arterial thrombosis in female patients with systemic rheumatic diseases

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al.

International consensus statement on an update of the classification

criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost.

2006;4:295–306.

2. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid

antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H).

Proc Natl Acad Sci U S A. 1990;87:4120–4.

3. Aǧar Ç, Van Os GMA, Mörgelin M, Sprenger RR, Marquart JA, Urbanus RT,

et al. β2-Glycoprotein I can exist in 2 conformations: implications for our

understanding of the antiphospholipid syndrome. Blood. 2010;116:1336–43.

4. de Laat B, van Berkel M, Urbanus RT, Siregar B, de Groot PG, Gebbink MF,

et al. Immune responses against domain I of β2-glycoprotein I are driven

by conformational changes: Domain I of β2-glycoprotein I harbors a

cryptic immunogenic epitope. Arthritis Rheum. 2011;63:3960–8.

5. De Laat B, Derksen RHWM, Urbanus RT, De Groot PG. IgG antibodies that

recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause

LAC, and their presence correlates strongly with thrombosis. Blood.

2005;105:1540–5.

6. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, et al. Efficacy

of the antiphospholipid score for the diagnosis of antiphospholipid

syndrome and its predictive value for thrombotic events. Arthritis Rheum.

2012;64:504–12.

7. Tanimura K, Jin H, Suenaga T, Morikami S, Arase N, Kishida K, et al.

β2-Glycoprotein I/HLA class II complexes are novel autoantigens in

antiphospholipid syndrome. Blood. 2015;125:2835–44.

8. Tanimura K, Saito S, Nakatsuka M, Nagamatsu T, Fujii T, Fukui A, et al.

The β 2-glycoprotein I/HLA–DR complex as a major autoantibody

target in obstetric antiphospholipid syndrome. Arthritis Rheumatol.

2020;72:1882–91.

9. Arase N, Tanimura K, Jin H, Yamaoka T, Kishibe M, Nishioka M, et al. Novel

autoantibody against the β2-glycoprotein I/human leucocyte antigen–

DR complex in patients with refractory cutaneous ulcers. Br J Dermatol.

2018;178:272–5.

10. Jiang Y, Arase N, Kohyama M, Hirayasu K, Suenaga T, Jin H, et al. Transport

of misfolded endoplasmic reticulum proteins to the cell surface by MHC

class II molecules. Int Immunol. 2013;25:235–46.

11. Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Palladini G,

et al. β2-Glycoprotein I (β2-GPI) mRNA is expressed by several cell types

involved in anti-phospholipid syndrome-related tissue damage. Clin Exp

Immunol. 1999;115:214–9.

12. Palli E, Kravvariti E, Tektonidou MG. Type I interferon signature in primary

antiphospholipid syndrome: clinical and laboratory associations. Front

Immunol. 2019;10:1–7.

13. Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid

antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic

events: a nationwide prospective study. Lupus. 2014;23:1468–76.

14. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear

CS, et al. Cardiovascular disease in autoimmune rheumatic diseases.

Autoimmun Rev. 2013;12:1004–15.

15. Hochberg MC. Updating the American college of rheumatology revised

criteria for the classification of systemic lupus erythematosus. Arthritis

Rheum. 1997;40:1725–1725. https://​doi.​org/​10.​1002/​art.​17804​00928.

16. Petri M, Orbai AM, Alarcõn GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating

clinics classification criteria for systemic lupus erythematosus. Arthritis

Rheum. 2012;64:2677–86.

17. Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, et al. 2019

Diagnostic criteria for mixed connective tissue disease (MCTD): From the

Japan research committee of the ministry of health, labor, and welfare for

systemic autoimmune diseases. Mod Rheumatol. 2021;31:29–33.

18. Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A,

et al. 2013 classification criteria for systemic sclerosis: an American College

of Rheumatology/European League Against Rheumatism collaborative

initiative. Ann Rheum Dis. 2013;72:1747–55.

19. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM,

et al. 2016 American College of Rheumatology/European League Against

Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient

cohorts. Arthritis Rheumatol. 2017;69:35–45.

Yoneda et al. Arthritis Research & Therapy

(2023) 25:195

20. Mok CC, Tang SSK, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic

groups. Arthritis Rheum. 2005;52:2774–82.

21. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R,

et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a

report of the American College of Cardiology/American Heart Association

Task Force on practice guidelines. Circulation. 2014;129:49–73.

22. Radin M, Schreiber K, Costanzo P, Cecchi I, Roccatello D, Baldovino S, et al.

The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk

stratification in young APS patients with acute myocardial infarction. Int J

Cardiol. 2017;240:72–7.

23. Song X, Fan Y, Jia Y, Li G, Liu M, Xu Y, et al. A novel aGAPSS-based nomogram

for the prediction of ischemic stroke in patients with antiphospholipid

syndrome. Front Immunol. 2022;13:1–11.

24. Di Minno MND, Scalera A, Tufano A, Ambrosino P, Bettiol A, Silvestri E, et al.

The association of adjusted Global AntiphosPholipid Syndrome Score

(aGAPSS) with cardiovascular disease in subjects with antiphospholipid

antibodies. Atherosclerosis. 2018;278:60–5.

25. Barilaro G, Esteves A, Della Rocca C, Perez-Isidro A, Araujo O, Pires da Rosa G,

et al. Predictive value of the adjusted Global Anti-Phospholipid Syndrome

Score on clinical recurrence in APS patients: a longitudinal study. Rheumatology. 2023;62:1576–85. https://​doi.​org/​10.​1093/​rheum​atolo​gy/​keac4​85.

26. Sciascia S, Radin M, Sanna G, Cecchi I, Roccatello D, Bertolaccini ML. Clinical

utility of the global anti-phospholipid syndrome score for risk stratification: a

pooled analysis. Rheumatol (United Kingdom). 2018;57:661–5.

27. de Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost. 2010;8:1540–6.

28. Fontana P, Poncet A, Lindhoff-Last E, de Moerloose P, Devreese KM. Refinement of the cutoff values of the HemosIL AcuStar assay for the detection

of anticardiolipin and anti–beta2 glycoprotein-1 antibodies. J Thromb

Haemost. 2014;12:2034–7.

29. Devreese KMJ, de Groot PG, de Laat B, Erkan D, Favaloro EJ, Mackie I, et al.

Guidance from the Scientific and Standardization Committee for lupus

anticoagulant/antiphospholipid antibodies of the International Society on

Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18:2828–39.

30. Tanimura K, Saito S, Tsuda S, Ono Y, Ota H, Wada S, et al. Anti-β2glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes. Int J Mol

Sci. 2023;24:10958.

31. Yagi M, Yasunaga H, Matsui H, Morita K, Fushimi K, Fujimoto M, et al. Impact

of Rehabilitation on Outcomes in Patients with Ischemic Stroke: a nationwide retrospective cohort study in Japan. Stroke. 2017;48:740–6.

32. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al.

Antithrombotic therapy for VTE disease: CHEST guideline and expert panel

report. Chest. 2016;149:315–52.

33. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, et al. Risk

factors for a first thrombotic event in antiphospholipid antibody carriers: a

prospective multicentre follow-up study. Ann Rheum Dis. 2011;70:1083–6.

34. Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence

of a first thromboembolic event in asymptomatic carriers of high-risk

antiphospholipid antibody profile: a multicenter prospective study. Blood.

2011;118:4714–8.

35. Fujieda Y, Atsumi T, Amengual O, Odani T, Otomo K, Kato M, et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus. 2012;21:1506–14.

36. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al.

Antiphospholipid syndrome: clinical and immunologic manifestations and

patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum.

2002;46:1019–27.

37. Hartung K, Coldewey R, Corvetta A, Deicher H, Kalden JR, Krapf F, et al. Mhc

gene products and anticardiolipin antibodies in systemic lupus erythematosus results of a multicenter study. Autoimmunity. 1992;13:95–9.

38. Hashimoto H, Yamanaka K, Tokano Y, Iida N, Takasaki Y, Kabasawa K, et al.

HLA-DRB1 alleles and beta 2 glycoprotein I-dependent anticardiolipin

antibodies in Japanese patients with systemic lupus erythematosus. Clin

Exp Rheumatol. 1998;16:423–7.

39. Oka S, Higuchi T, Furukawa H, Shimada K, Hashimoto A, Komiya A, et al. Predisposition of HLA-DRB1*04:01/*15 heterozygous genotypes to Japanese

mixed connective tissue disease. Sci Rep. 2022;12:1–9.

Page 15 of 15

40. Jin H, Arase N, Hirayasu K, Kohyama M, Suenaga T, Saito F, et al. Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis

susceptibility. Proc Natl Acad Sci U S A. 2014;111:3787–92.

41. Collins T, Korman AJ, Wake CT, Boss JM, Kappes DJ, Fiers W, et al. Immune

interferon activates multiple class II major histocompatibility complex genes

and the associated invariant chain gene in human endothelial cells and

dermal fibroblasts. Proc Natl Acad Sci U S A. 1984;81:4917–21.

42. Pober JS, Gimbrone MA, Cotran RS, Reiss CS, Burakoff SJ, Fiers W, et al. Ia

expression by vascular endothelium is inducible by activated T cells and by

human gamma interferon. J Exp Med. 1983;157:1339–53.

43. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with

systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum

Dis. 2011;70:2029–36.

44. Cecchi I, Radin M, Rodríguez-Carrio J, Tambralli A, Knight JS, Sciascia S. Utilizing type I interferon expression in the identification of antiphospholipid

syndrome subsets. Expert Rev Clin Immunol. 2021;17:395–406.

45. Hisada RYO, Kato M, Sugawara ERI, Kanda M, Fujieda Y, Oku K, et al. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation. J Thromb Haemost.

2019;17:1134–43.

46. Wang X, Zhu X, Zhou H, Xia L, Wang T, Wang Z, et al. Anti-β2GPI antibodies enhance atherosclerosis in ApoE-deficient mice. Biochem Biophys Res

Commun. 2019;512:72–8.

47. Tektonidou MG. Cardiovascular disease risk in antiphospholipid syndrome:

Thrombo-inflammation and atherothrombosis. J Autoimmun. 2022;128:

102813.

48. Gandhi AA, Estes SK, Rysenga CE, Knight JS. Understanding the pathophysiology of thrombotic aps through animal models. Int J Mol Sci. 2021;22:1–15.

49. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in

antiphospholipid syndrome. Rheumatology. 2002;41:924–9.

50. Cook NR. Use and misuse of the receiver operating characteristic curve in

risk prediction. Circulation. 2007;115:928–35.

51. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N,

et al. Assessing the performance of prediction models. Epidemiology.

2010;21:128–38.

52. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting

of a multivariable prediction model for individual prognosis or diagnosis

(TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594–g7594.

53. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with

systemic lupus erythematosus. Ann Rheum Dis. 2003;62:1071–7.

54. Park DJ, Yoon CS, Choi SE, Xu H, Kang JH, Lee SS. Risk factors for thrombotic

events in Korean patients with systemic lupus erythematosus. Sci Rep.

2021;11:1–8.

55. Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR

recommendations for cardiovascular risk management in rheumatic and

musculoskeletal diseases, including systemic lupus erythematosus and

antiphospholipid syndrome. Ann Rheum Dis. 2022;81:768–79.

56. Balbi GGM, Ahmadzadeh Y, Tektonidou MG, Pengo V, Sciascia S, Ugarte A,

et al. Damage measured by Damage Index for Antiphospholipid Syndrome

(DIAPS) in antiphospholipid antibody-positive patients included in the APS

ACTION registry. Rheumatology. 2023;kead292. https://​doi.​org/​10.​1093/​

rheum​atolo​gy/​kead2​92.

57. Qi W, Zhao J, Huang C, Jiang N, Li J, Wu C, et al. Clinical characteristics and

prognosis of patients with antiphospholipid antibodies based on cluster

analysis: an 8-year cohort study. Arthritis Res Ther. 2022;24:1–13.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

...